{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:59:41Z","timestamp":1780466381584,"version":"3.54.1"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ek0109347h0003"],"award-info":[{"award-number":["20ek0109347h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21lm0203007j0005"],"award-info":[{"award-number":["21lm0203007j0005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22ym0126809j0001"],"award-info":[{"award-number":["22ym0126809j0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JP21K08322"],"award-info":[{"award-number":["JP21K08322"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["20FC1043"],"award-info":[{"award-number":["20FC1043"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.neuropharm.2022.109203","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T20:54:04Z","timestamp":1659473644000},"page":"109203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice"],"prefix":"10.1016","volume":"218","author":[{"given":"Makiko","family":"Koike-Kumagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Wataya-Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109203_bib1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.bbi.2020.07.026","article-title":"Purinergic signaling in infectious diseases of the central nervous system","volume":"89","author":"Alves","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2022.109203_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3233\/JAD-160324","article-title":"Adenosine type A2A receptor in peripheral cell from patients with Alzheimer's disease, vascular dementia, and idiopathic normal pressure hydrocephalus: a new\/old potential target","volume":"54","author":"Arosio","year":"2016","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.neuropharm.2022.109203_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","article-title":"Rapamycin and mTOR kinase inhibitors","volume":"1","author":"Ballou","year":"2008","journal-title":"J. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jneumeth.2013.07.017","article-title":"Immunomagnetic enrichment and flow cytometric characterization of mouse microglia","volume":"219","author":"Bedi","year":"2013","journal-title":"J. Neurosci. Methods"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109203_bib95","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/epi.12960","article-title":"Complex alterations in microglial M1\/M2 markers during the development of epilepsy in two mouse models","volume":"56","author":"Benson","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109203_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1152\/physrev.00043.2006","article-title":"Physiology and pathophysiology of purinergic neurotransmission","volume":"87","author":"Burnstock","year":"2007","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109203_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pneurobio.2011.08.006","article-title":"Purinergic signalling: from normal behaviour to pathological brain function","volume":"95","author":"Burnstock","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib7","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1038\/ncomms3834","article-title":"The TSC-mTOR pathway regulates macrophage polarization","volume":"4","author":"Byles","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2022.109203_bib8","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","article-title":"Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex","volume":"164","author":"Cardamone","year":"2014","journal-title":"J. Pediatr."},{"key":"10.1016\/j.neuropharm.2022.109203_bib9","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1007\/s00381-021-05218-4","article-title":"Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in tuberous sclerosis complex: a case report","volume":"37","author":"Cavalheiro","year":"2021","journal-title":"Child\u2019s Nerv. Syst."},{"key":"10.1016\/j.neuropharm.2022.109203_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/B978-0-12-801022-8.00012-X","article-title":"Adenosine receptor control of cognition in normal and disease","volume":"119","author":"Chen","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A 2A receptor antagonist istradefylline for treatment of Parkinson's disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2022.109203_bib12","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109203_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00605","article-title":"Modulation of microglial activation by adenosine A2a receptor in animal models of perinatal brain injury","volume":"9","author":"Colella","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00605","article-title":"Modulation of microglial activation by adenosine A2a receptor in animal models of perinatal brain injury","volume":"9","author":"Colella","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib15","doi-asserted-by":"crossref","unstructured":"Crino, P.B., Nathanson, K.L., Henske, E.P., 2009. The Tuberous Sclerosis Complex. https:\/\/doi.org\/10.1056\/NEJMra055323 355, 1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMRA055323.","DOI":"10.1056\/NEJMra055323"},{"key":"10.1016\/j.neuropharm.2022.109203_bib16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and neuropsychiatric aspects of tuberous sclerosis complex","volume":"14","author":"Curatolo","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1515\/rns.2011.020","article-title":"Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury","volume":"22","author":"Dai","year":"2011","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/nn1472","article-title":"ATP mediates rapid microglial response to local brain injury in vivo","volume":"8","author":"Davalos","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib19","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/nn1472","article-title":"ATP mediates rapid microglial response to local brain injury in vivo","volume":"8","author":"Davalos","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","article-title":"Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist","volume":"52","author":"De Vries","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.c.31637","article-title":"A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)","author":"De Vries","year":"2018","journal-title":"Am. J. Med. Genet. Part C Semin. Med. Genet."},{"key":"10.1016\/j.neuropharm.2022.109203_bib22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bbr.2012.01.017","article-title":"Blocking mTORC1 activity by rapamycin leads to impairment of spatial memory retrieval but not acquisition in C57BL\/6J mice","volume":"229","author":"Deli","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109203_bib23","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.jocn.2015.03.035","article-title":"Olfactory abnormalities in temporal lobe epilepsy","volume":"22","author":"Desai","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","article-title":"The P2X7 receptor in infection and inflammation","volume":"47","author":"Di Virgilio","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.neuropharm.2022.109203_bib25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1788","article-title":"Reversal of learning deficits in a Tsc2+\/\u2212 mouse model of tuberous sclerosis","volume":"14","author":"Ehninger","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2022.109203_bib26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jns.2012.05.030","article-title":"Mitochondria, oxidative stress and neurodegeneration","volume":"322","author":"Federico","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neuroscience.2015.07.041","article-title":"Bidirectional modulation of anxiety-related and social behaviors by amygdala projections to the medial prefrontal cortex","volume":"321","author":"Felix-Ortiz","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109203_bib28","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2022.109203_bib29","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1007\/s12035-013-8620-6","article-title":"Phagocytosis of microglia in the central nervous system diseases","volume":"49","author":"Fu","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pneurobio.2013.10.004","article-title":"Autophagy and apoptosis dysfunction in neurodegenerative disorders","volume":"112","author":"Ghavami","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib31","first-page":"417","article-title":"Whole-mount X-gal staining of mouse tissues","author":"Gierut","year":"2014","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.neuropharm.2022.109203_bib32","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.11110.1","article-title":"New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND)","volume":"6","author":"Gipson","year":"2017","journal-title":"F1000Research"},{"key":"10.1016\/j.neuropharm.2022.109203_bib33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.clpt.6100317","article-title":"Rapamycin: something old, something new, sometimes borrowed and now renewed","volume":"82","author":"Hartford","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109203_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045156","article-title":"The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice","volume":"7","author":"Hartman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2022.109203_bib35","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/nn1805","article-title":"The P2Y12 receptor regulates microglial activation by extracellular nucleotides","volume":"9","author":"Haynes","year":"2006","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-020-01987-y","article-title":"Sestrin2 regulates microglia polarization through mTOR-mediated autophagic flux to attenuate inflammation during experimental brain ischemia","volume":"17","author":"He","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2022.109203_bib37","author":"Hiragi"},{"key":"10.1016\/j.neuropharm.2022.109203_bib38","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.21-06-01975.2001","article-title":"Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi\/o-coupled P2Y receptors","volume":"21","author":"Honda","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0166-4328(02)00183-3","article-title":"Characteristics of changes in cholinergic function and impairment of learning and memory-related behavior induced by olfactory bulbectomy","volume":"138","author":"Hozumi","year":"2003","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109203_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neuroscience.2019.11.029","article-title":"Evaluation of Fluoro-Jade C staining: specificity and application to damaged immature neuronal cells in the normal and injured mouse brain","volume":"425","author":"Ikenari","year":"2020","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109203_bib41","author":"Illes"},{"key":"10.1016\/j.neuropharm.2022.109203_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40810-015-0004-x","article-title":"Everolimus improves behavioral deficits in a patient with autism associated with tuberous sclerosis: a case report","volume":"1","author":"Ishii","year":"2015","journal-title":"Neuropsychiatr. Electrophysiol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib43","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.exger.2006.11.012","article-title":"Induction of matrix metalloproteinases (MMP3, MMP12 and MMP13) expression in the microglia by amyloid-beta stimulation via the PI3K\/Akt pathway","volume":"42","author":"Ito","year":"2007","journal-title":"Exp. Gerontol."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109203_bib96","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1006\/dbio.2000.0106","article-title":"Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo","volume":"230","author":"Kisanuki","year":"2001","journal-title":"Dev. Biol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib45","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2022.109203_bib46","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with everolimus in tuberous sclerosis","volume":"87","author":"Krueger","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2022.109203_bib47","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/acn3.494","article-title":"Everolimus for treatment of tuberous sclerosis complex\u2010associated neuropsychiatric disorders","volume":"4","author":"Krueger","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pediatrneurol.2014.10.006","article-title":"Pilot validation of the tuberous sclerosis-associated neuropsychiatric disorders (TAND) checklist","volume":"52","author":"Leclezio","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib49","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1096\/fj.201600495R","article-title":"mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type","volume":"30","author":"Li","year":"2016","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2022.109203_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","article-title":"The Neurology of mTOR","volume":"84","author":"Lipton","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109203_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-11-125","article-title":"The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype","volume":"11","author":"Lisi","year":"2014","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2022.109203_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainres.2018.06.021","article-title":"Adenosine binds predominantly to adenosine receptor A1 subtype in astrocytes and mediates an immunosuppressive effect","volume":"1700","author":"Liu","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109203_bib53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pneurobio.2016.01.005","article-title":"The biphasic function of microglia in ischemic stroke","volume":"157","author":"Ma","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib54","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS amyloid-\u03b2 in Alzheimer's disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109203_bib55","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00726-014-1765-4","article-title":"Regulation of autophagy by amino acids and MTOR-dependent signal transduction","volume":"47","author":"Meijer","year":"2015","journal-title":"Amino Acids"},{"key":"10.1016\/j.neuropharm.2022.109203_bib56","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/imm.12126","article-title":"Rapamycin unbalances the polarization of human macrophages to M1","volume":"140","author":"Mercalli","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.neuropharm.2022.109203_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2009.02.003","article-title":"Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-\u03b2","volume":"210","author":"Michelucci","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib58","doi-asserted-by":"crossref","DOI":"10.1186\/1824-7288-39-57","article-title":"Is mTOR inhibition a systemic treatment for tuberous sclerosis?","volume":"39","author":"Moavero","year":"2013","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.neuropharm.2022.109203_bib59","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1212\/NXI.0000000000000080","article-title":"P2Y12 expression and function in alternatively activated human microglia","volume":"2","author":"Moore","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"key":"10.1016\/j.neuropharm.2022.109203_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041899","article-title":"A smell that causes seizure","volume":"7","author":"Nguyen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2022.109203_bib61","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.neuron.2013.03.030","article-title":"Temporal and mosaic Tsc1 deletion in the developing thalamus disrupts thalamocortical circuitry, neural function, and behavior","volume":"78","author":"Normand","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109203_bib62","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/glia.20489","article-title":"Involvement of P2X4 and P2Y12 receptors in ATP-induced microglial chemotaxis","volume":"55","author":"Ohsawa","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2022.109203_bib63","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1471-4159.2012.07693.x","article-title":"Adenosine A3 receptor is involved in ADP-induced microglial process extension and migration","volume":"121","author":"Ohsawa","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2022.109203_bib64","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1749-6632.2009.05117.x","article-title":"The tuberous sclerosis complex","volume":"1184","author":"Orlova","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib65","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1212\/WNL.0000000000007749","article-title":"A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex","volume":"93","author":"Overwater","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2022.109203_bib66","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1126\/science.1202529","article-title":"Synaptic pruning by microglia is necessary for normal brain development","volume":"333","author":"Paolicelli","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109203_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-021-09357-2","article-title":"mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus","volume":"13","author":"Petrasek","year":"2021","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.neuropharm.2022.109203_bib68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nbd.2012.10.014","article-title":"Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex","volume":"51","author":"Reith","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109203_bib69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11302-006-9003-5","article-title":"The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance","volume":"2","author":"Robson","year":"2006","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2022.109203_bib70","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1042\/BST20130134","article-title":"Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers","volume":"41","author":"Sarkar","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2022.109203_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011272.pub2","article-title":"Rapamycin and rapalogs for tuberous sclerosis complex","author":"Sasongko","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2022.109203_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms2295","article-title":"Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex","volume":"3","author":"Sato","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2022.109203_bib73","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109203_bib74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1385-299X(96)00006-2","article-title":"5\u2019-nucleotidase enzyme cytochemistry as a tool for revealing activated glial cells and malleable synapses in CNS development and regeneration","volume":"1","author":"Schoen","year":"1997","journal-title":"Brain Res. Brain Res. Protoc."},{"key":"10.1016\/j.neuropharm.2022.109203_bib75","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.nbd.2018.05.024","article-title":"Blockade of adenosine A 2A receptors recovers early deficits of memory and plasticity in the triple transgenic mouse model of Alzheimer's disease","volume":"117","author":"Silva","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109203_bib76","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib77","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","article-title":"The classical complement cascade mediates CNS synapse elimination","volume":"131","author":"Stevens","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109203_bib78","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1073\/pnas.1014715108","article-title":"Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage","volume":"108","author":"Stoica","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2022.109203_bib79","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/glia.10154","article-title":"Microglia as neuroprotective, immunocompetent cells of the CNS","volume":"40","author":"Streit","year":"2002","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2022.109203_bib80","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.neurobiolaging.2007.04.006","article-title":"Synuclein activates microglia in a model of Parkinson's disease","volume":"29","author":"Su","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2022.109203_bib81","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.neuron.2014.07.040","article-title":"Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits","volume":"83","author":"Tang","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109203_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000527","article-title":"Microglial interactions with synapses are modulated by visual experience","volume":"8","author":"Tremblay","year":"2010","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib83","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/glia.22516","article-title":"Involvement of P2X4 receptors in hippocampal microglial activation after status epilepticus","volume":"61","author":"Ulmann","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2022.109203_bib84","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1523\/JNEUROSCI.2239-16.2016","article-title":"A novel focal seizure pattern generated in superficial layers of the olfactory cortex","volume":"37","author":"Uva","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib85","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/hmg\/ddn376","article-title":"Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy","volume":"18","author":"Villalta","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109203_bib86","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1523\/JNEUROSCI.4363-08.2009","article-title":"Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals","volume":"29","author":"Wake","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib87","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.immuni.2008.08.012","article-title":"The TSC-mTOR signaling pathway regulates the innate inflammatory response","volume":"29","author":"Weichhart","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.neuropharm.2022.109203_bib88","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0166-4328(97)86046-9","article-title":"Characteristics of memory dysfunction in olfactory bulbectomized rats and the effects of cholinergic drugs","volume":"83","author":"Yamamoto","year":"1997","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109203_bib89","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jid.2017.10.007","article-title":"Uncoupling of ER\/mitochondrial oxidative stress in mTORC1 hyperactivation-associated skin hypopigmentation","volume":"138","author":"Yang","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib90","article-title":"Epilepsy in a melanocyte-lineage mTOR hyperactivation mouse model: a novel epilepsy model","volume":"15","author":"Yang","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2022.109203_bib91","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109203_bib92","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1523\/JNEUROSCI.0066-09.2009","article-title":"The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy","volume":"29","author":"Zeng","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109203_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2017.00077","article-title":"Microglia polarization with M1\/M2 phenotype changes in rd1 mouse model of retinal degeneration","volume":"11","author":"Zhou","year":"2017","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuropharm.2022.109203_bib94","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11302-012-9309-4","article-title":"Cellular function and molecular structure of ecto-nucleotidases","volume":"8","author":"Zimmermann","year":"2012","journal-title":"Purinergic Signal."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:19:44Z","timestamp":1758439184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822002623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":96,"alternative-id":["S0028390822002623"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109203","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109203"}}